BMAL1 and neoplasm: As anticipated, miR-135b overexpression promoted the growth of subcutaneous xenografts generated by MIA PaCa-2 cells, whereas BMAL1 reintroduction sensitised the cell response to GEM therapy and substantially reduced the sizes and weights of tumours (Fig. 6c, d).